Octreotide (Sandostatin)
PeptideOctreotide is a synthetic octapeptide analog of somatostatin with prolonged action. FDA-approved in 1988, it is available as immediate-release injection and long-acting repeatable (LAR) formulation. Primary indications include acromegaly, carcinoid syndrome, and neuroendocrine tumors. The PROMID trial demonstrated significant antiproliferative effects in midgut neuroendocrine tumors, and multiple trials confirm efficacy for GH/IGF-1 suppression in acromegaly.
Quick Answer
What it is
Octreotide is a synthetic octapeptide analog of somatostatin with prolonged action. FDA-approved in 1988, it is available as immediate-release injection and long-acting repeatable (LAR) formulation.
Key findings
- Grade A: Tumor Progression (NETs) (Neuroendocrine Tumors)
- Grade A: Carcinoid Syndrome Symptoms (Neuroendocrine Tumors)
- Grade A: GH Suppression (Acromegaly) (Acromegaly)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Octreotide (Sandostatin)
Quick Facts: Octreotide (Sandostatin)
- Best Evidence:Grade A
- Conditions Studied:2
- Research Outcomes:13
- Grade A Findings:6
- Grade B Findings:4
- Key Effect:Neuroendocrine Tumors
Detailed Outcomes
Evidence by Condition
Research Citations (49)
Related Peptides
Lanreotide (Somatuline)
Peptide2 shared conditions · 14 outcomes
Lanreotide is a long-acting synthetic octapeptide analog of somatostatin, FDA-approved for treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The landmark CLARINET trial demonstrated 53% reduction in disease progression risk in metastatic GEP-NETs. Available as an extended-release depot formulation (Somatuline Depot) for once-monthly injection.
Pegvisomant (Somavert)
Peptide1 shared condition · 10 outcomes
Pegvisomant is a genetically modified growth hormone analog that functions as a GH receptor antagonist. FDA-approved in 2003, it is the first and only GH receptor antagonist for acromegaly. It is indicated for patients with inadequate response to surgery, radiation, or somatostatin analogs. Phase III trials showed up to 97% of patients achieving IGF-1 normalization with long-term treatment, making it the most effective medical therapy for biochemical control.
Pasireotide (Signifor)
Peptide1 shared condition · 10 outcomes
Pasireotide is a novel multi-receptor-targeted somatostatin analog with high affinity for somatostatin receptor subtypes 1, 2, 3, and 5. FDA-approved in 2012, it is the first pituitary-directed medication for Cushing's disease. Available as twice-daily subcutaneous injection (Signifor) and long-acting monthly injection (Signifor LAR) for acromegaly. The Phase III PASPORT trial demonstrated significant urinary free cortisol normalization in Cushing's disease patients.
Lutetium-177 Dotatate (Lutathera)
Peptide1 shared condition · 10 outcomes
Lutetium-177 dotatate is a radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT). FDA-approved 2018 for SSTR-positive GEP-NETs. NETTER-1 Phase 3: 65.2% PFS at 20 months vs 10.8% control. 79% reduction in disease progression/death risk. Median OS 48 months vs 36.3 months. First radiopharmaceutical for NETs.